BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Cervomed Inc.

Headquarters: Cambridge, MA, United States
Year Founded: 2010
Status: Public
Industry Sector: CommercialServices
CEO: John J. Alam, MD
Number Of Employees: 15
Enterprise Value: $-20,030,836
PE Ratio: -4.93
Exchange/Ticker 1: NASDAQ:CRVO
Exchange/Ticker 2: N/A
Latest Market Cap: $89,202,904

BioCentury | Nov 19, 2024
Product Development

An understudied dementia soon to get a pair of Phase II readouts

CervoMed and Cognition Therapeutics testing different therapeutic hypotheses in dementia with Lewy bodies
BioCentury | May 20, 2024
Management Tracks

Chroma hires Jenny Marlowe as CDO

Plus: William Elder named CFO of CervoMed, and updates from Xspray and Senti
BioCentury | Apr 2, 2024
Product Development

Neurology’s false choice: symptomatic vs. disease-modifying

A new theme in Alzheimer’s is aiming for early symptom relief PLUS long-term disease modification
BioCentury | Mar 29, 2024
Finance

Public equity report: Avalo gets makeover with PIPE, acquisition

Plus: A PIPE for CervoMed ahead of dementia readout; and Stoke, Praxis follow clinical readouts with opportunistic follow-ons
Items per page:
1 - 4 of 4